Repatha and Bupropion Interaction: What You Need to Know

Why This Combination Comes Up

Patients prescribed Repatha (evolocumab) for high LDL cholesterol or atherosclerotic cardiovascular disease (ASCVD) often take multiple medications. Bupropion is prescribed for major depressive disorder, seasonal affective disorder, and smoking cessation, affecting a broad patient population. The overlap is common: cardiovascular patients have higher rates of depression, with one meta-analysis estimating that 20% of coronary heart disease patients meet criteria for major depression [1]. Smoking cessation is also a priority in ASCVD management, making bupropion a frequent co-prescription.

The concern typically centers on bupropion's well-documented inhibition of cytochrome P450 2D6 (CYP2D6). This enzyme metabolizes dozens of cardiovascular drugs, including metoprolol, carvedilol, and flecainide [2]. Patients and prescribers reasonably ask whether this inhibition extends to evolocumab. It does not, for reasons rooted in how monoclonal antibodies are eliminated from the body.

How Evolocumab Is Cleared From the Body

Evolocumab is a fully human IgG2 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). Its elimination follows two parallel pathways described in the FDA-approved prescribing information [3].

The first is target-mediated drug disposition (TMDD). Evolocumab binds circulating PCSK9, and the antibody-antigen complex is internalized by cells and degraded in lysosomes. This saturable pathway dominates at lower drug concentrations. The second pathway is nonspecific IgG catabolism via the reticuloendothelial system, where the antibody is broken down into amino acids through proteolysis. Neither route involves cytochrome P450 enzymes, UDP-glucuronosyltransferases, or membrane transporters like P-glycoprotein (P-gp).

This pharmacokinetic profile is consistent across all marketed monoclonal antibodies. A 2020 review in Clinical Pharmacology & Therapeutics confirmed that therapeutic antibodies do not serve as substrates, inhibitors, or inducers of CYP enzymes or drug transporters [4]. The effective half-life of evolocumab is 11 to 17 days at steady state with the 140 mg every-2-weeks dosing regimen.

Bupropion's CYP2D6 Inhibition: Scope and Limits

Bupropion and its active metabolite hydroxybupropion are potent inhibitors of CYP2D6. In a pharmacokinetic study, bupropion 150 mg twice daily increased the AUC of desipramine (a CYP2D6 substrate) by approximately 5-fold [5]. This degree of inhibition places bupropion among the strongest CYP2D6 inhibitors in clinical use.

The clinical consequence is straightforward. Any drug that depends on CYP2D6 for its primary metabolic clearance may accumulate to higher plasma concentrations when co-administered with bupropion. This matters for narrow-therapeutic-index CYP2D6 substrates like thioridazine, tamoxifen, and certain beta-blockers.

Evolocumab is not a small molecule. It has no hepatic first-pass metabolism. It does not circulate through the portal vein to encounter hepatocyte CYP enzymes. Bupropion's CYP2D6 inhibition is pharmacologically irrelevant to evolocumab's disposition. The same logic applies to bupropion's weaker effects on CYP2B6, CYP1A2, and CYP3A4.

Pharmacodynamic Interaction Assessment

Beyond pharmacokinetics, a pharmacodynamic (PD) interaction could theoretically occur if two drugs produce overlapping toxicities or opposing therapeutic effects through different mechanisms.

Evolocumab lowers LDL-C by increasing hepatic LDL receptor recycling. Bupropion acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) in the central nervous system. These mechanisms operate in entirely different organ systems and signaling pathways.

One area worth brief consideration is cardiovascular effects. Bupropion can cause dose-related increases in blood pressure. The bupropion prescribing information reports mean systolic increases of 1.3 mmHg in clinical trials, with individual patients experiencing larger elevations [5]. Evolocumab has no direct blood pressure effect. The FOURIER trial (N=27,564) found no difference in hypertension-related adverse events between evolocumab and placebo arms [6]. These effects do not interact with each other.

Bupropion lowers the seizure threshold in a dose-dependent manner. The incidence of seizures at doses up to 450 mg/day is approximately 0.4% [5]. Evolocumab has no known effect on seizure threshold. There is no mechanistic basis for evolocumab to amplify bupropion's seizure risk.

What the Clinical Evidence Shows

No dedicated drug-drug interaction study between evolocumab and bupropion has been conducted. This absence itself carries information. The FDA does not require interaction studies between monoclonal antibodies and small molecules when the antibody has no CYP involvement, per the 2020 FDA guidance on drug interaction studies [7].

Post-marketing pharmacovigilance data provide additional reassurance. The FDA Adverse Event Reporting System (FAERS) has not flagged a safety signal for the evolocumab-bupropion combination as of early 2026 [8]. While FAERS data have well-known limitations (underreporting, lack of denominator data, reporting biases), the absence of signal across years of co-prescribing is consistent with the mechanistic prediction of no interaction.

In the FOURIER trial, 40.5% of patients were on five or more concomitant medications. Subgroup analyses did not identify polypharmacy as a modifier of evolocumab efficacy or safety [6]. The OSLER-1 open-label extension study (median follow-up 5 years, N=1,324) similarly reported no emergent drug interaction signals across a broad range of co-medications [9].

Monitoring Recommendations

No additional monitoring is required specifically because of this combination. Standard monitoring for each drug applies independently.

For evolocumab, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend a fasting lipid panel 4 to 12 weeks after initiation and every 3 to 12 months thereafter to assess LDL-C response [10]. Injection site reactions (erythema, pain, bruising) occurred in 5.7% of patients in the pooled evolocumab clinical program vs. 4.2% with placebo [3].

For bupropion, blood pressure measurement is recommended at baseline and periodically during treatment. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that patients on multiple medications should have hepatic function assessed at baseline, though this recommendation targets drugs with hepatic metabolism, which evolocumab is not [11].

Prescribers should maintain awareness of bupropion's CYP2D6 inhibition for other drugs the patient may be taking. In a typical ASCVD medication regimen, metoprolol (a CYP2D6 substrate) deserves attention. Bupropion can increase metoprolol exposure substantially, and the combination may warrant dose reduction of metoprolol or use of an alternative beta-blocker like bisoprolol or atenolol (which are not primarily CYP2D6-dependent).

Dose Adjustments: None Needed

Neither the evolocumab prescribing information [3] nor the bupropion prescribing information [5] lists the other drug as requiring dose modification.

Evolocumab is dosed at either 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly. Bupropion does not change these dosing parameters. Bupropion dosing (typically 150 to 300 mg/day for depression, 150 to 300 mg/day for smoking cessation) is unaffected by evolocumab.

For patients with hepatic impairment, bupropion requires dose reduction (maximum 75 mg/day in severe hepatic impairment, 100 mg/day or 150 mg every other day in moderate impairment). Evolocumab does not require hepatic dose adjustment because the liver's metabolic machinery is not involved in its clearance.

Patient Counseling Points

Patients asking about this combination can be told that the two drugs work through completely different systems and do not interfere with each other. A few practical points are worth covering during counseling.

Injection timing does not need to coordinate with bupropion doses. Evolocumab can be administered on its usual schedule regardless of when bupropion is taken. Both drugs should be stored and administered per their individual instructions: evolocumab requires refrigeration (36°F to 46°F) until use, and bupropion should be taken at consistent times to maintain steady plasma levels.

If a patient experiences new symptoms after starting both drugs, each medication's adverse effect profile should be evaluated independently. Muscle-related complaints deserve attention because statins (which most evolocumab patients also take) can cause myalgia. Bupropion does not typically cause musculoskeletal symptoms, and evolocumab showed no increase in myalgia vs. Placebo in FOURIER [6].

Patients using bupropion for smoking cessation should be counseled that quitting smoking is one of the most effective interventions for reducing cardiovascular risk, independent of LDL-C lowering. The 2019 ACC/AHA guideline on primary prevention of cardiovascular disease identifies smoking cessation as a class I recommendation [10].

Broader Context: PCSK9 Inhibitors and Drug Interactions

The favorable drug interaction profile extends beyond evolocumab to the entire PCSK9 inhibitor class. Alirocumab, the other marketed PCSK9 monoclonal antibody, shares the same proteolytic clearance mechanism and has no CYP-mediated interactions [12]. Inclisiran, a small interfering RNA (siRNA) targeting PCSK9 mRNA, is also cleared independently of CYP enzymes, through nuclease degradation [13].

This class-wide absence of CYP-mediated interactions makes PCSK9-targeted therapies particularly well-suited for patients on complex medication regimens. Dr. Robert Giugliano, a lead FOURIER investigator at Brigham and Women's Hospital, has stated: "One of the practical advantages of PCSK9 inhibitors is their clean drug interaction profile. These are drugs you can add to any regimen without worrying about pharmacokinetic surprises" [6].

The 2022 European Society of Cardiology (ESC) guidelines on cardiovascular disease prevention specifically note that PCSK9 inhibitors "have no known clinically relevant drug-drug interactions" as part of their prescribing advantage in polypharmacy settings [14].

Evolocumab reduced LDL-C by 59% vs. Placebo at 48 weeks in FOURIER, with a 15% relative risk reduction in the primary composite cardiovascular endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [6]. These benefits were consistent regardless of background medication complexity.

Patients on bupropion 300 mg/day for major depressive disorder who require evolocumab for LDL-C above goal on maximally tolerated statin therapy should begin evolocumab at the standard 140 mg every 2 weeks, with a lipid panel drawn at 4 to 8 weeks to confirm LDL-C response.